阿奇霉素与多西环素治疗生殖道沙眼衣原体感染疗效的Meta分析

doi:10.3760/cma.j.issn.0412-4030.2018.09.019

摘要/Abstract

摘要： 目的系统评价阿奇霉素与多西环素治疗生殖道沙眼衣原体感染的疗效。方法计算机检索Cochrane图书馆、PubMed、EMBASE、CBMdisc、CNKI和万方数据库，搜索关于阿奇霉素与多西环素治疗生殖道沙眼衣原体感染的临床随机对照试验（RCT），以微生物学转阴作为判愈标准。治疗组采用阿奇霉素治疗，对照组采用多西环素治疗。检索时间为1980年1月1日至2017年10月。由两名研究者共同独立提取资料并评估纳入研究质量。采用 Stata?12.0软件对试验数据进行统计分析。结果共纳入24篇文章，包括24个RCT、2 369例患者，阿奇霉素治疗组1 302例，多西环素治疗组1 067例。Meta分析结果显示，阿奇霉素与多西环素治疗生殖道沙眼衣原体感染的微生物学有效率差异有统计学意义。采用固定效应模型对数据合并分析后显示，多西环素有效率优于阿奇霉素，有效率差异为2.8%（95% CI，0.9% ~ 4.6%）。结论阿奇霉素治疗生殖道沙眼衣原体感染后的微生物学有效率低于多西环素，但临床应用的确切疗效尚需更多的RCT证实。

关键词: 沙眼衣原体, 叠氮红霉素, 多西环素, 治疗结果, Meta分析

Abstract: Qin Bei, Liu Quanzhong Department of Dermatology and Venereology, Tianjin Medical University General Hospital, Tianjin 300052, China Corresponding author: Liu Quanzhong, Email: liuquanzhong@medmail.com.cn 【Abstract】 Objective To systematically evaluate the efficacy of azithromycin and doxycycline in the treatment of genital Chlamydia trachomatis infection. Methods Databases including Cochrane library, PubMed, EMBASE, CBMdisc, CNKI and Wanfang were searched from January 1, 1980 to October 2017 for randomized controlled trials （RCTs） comparing the efficacy of azithromycin versus doxycycline in the treatment of genital Chlamydia trachomatis infection. In these RCTs, negative microbiological findings were defined as cure. Patients in the treatment group were treated with azithromycin, and those in the control group were treated with doxycycline. Two researchers independently extracted data and evaluated the quality of these RCTs. Statistical analysis was done by using Stata 12.0 software. Results A total of 24 research reports were enrolled, including 24 RCTs and 2 369 patients. There were 1 302 patients in the azithromycin group and 1 067 in the doxycycline group. Meta-analysis showed that there was a significant difference in the microbiological response rate between the treatment group and the control group. A fixed-effect model was used to combine the response rate, and showed that the response rate to doxycycline was superior to that to azithromycin, with a risk difference of 2.8% （95% CI, 0.9% - 4.6%）. Conclusion The microbiological response rate to azithromycin is lower than that to doxycycline in the treatment of genital Chlamydia trachomatis infection, but more RCTs are required to confirm the clinical efficacy of doxycycline.

Key words: Chlamydia trachomatis, Azithromycin, Doxycycline, Treatment outcome, Meta?analysis

秦蓓刘全忠. 阿奇霉素与多西环素治疗生殖道沙眼衣原体感染疗效的Meta分析[J]. 中华皮肤科杂志, 2018, 51(9): 691-695.

Qin-Bei quanzhong liu. Efficacy of azithromycin versus doxycycline in the treatment of genital Chlamydia trachomatis infection: a meta-analysis[J]. Chinese Journal of Dermatology, 2018, 51(9): 691-695.

参考文献 35

［1］	Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015［J］. MMWR Recomm Rep, 2015,64（RR⁃03）:1⁃137.<br />
［2］	Walker J, Tabrizi SN, Fairley CK, et al. Chlamydia trachomatis incidence and re⁃infection among young women⁃⁃behavioural and microbiological characteristics［J］. PLoS One, 2012,7（5）:e37778. doi: 10.1371/journal.pone.0037778.<br />
［3］	Scott LD, Baster K, Emmett L, et al. Incidence and reinfection rates of genital chlamydial infection among women aged 16⁃24 years attending general practice, family planning and genitourinary medicine clinics in England: a prospective cohort study by the Chlamydia Recall Study Advisory Group［J］. Sex Transm Infect, 2007,83（4）:292⁃303. doi: 10.1136/sti.2006.022053.<br />
［4］	Batteiger BE, Tu W, Ofner S, et al. Repeated Chlamydia trachomatis genital infections in adolescent women［J］. J Infect Dis, 2010,201（1）:42⁃51. doi: 10.1086/648734.<br />
［5］	Golden MR, Whittington WL, Handsfield HH, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection［J］. N Engl J Med, 2005,352（7）:676⁃685. doi: 10.1056/NEJMoa041681.<br />
［6］	Steingrimsson O, Olafsson JH, Thorarinsson H, et al. Azithromycin in the treatment of sexually transmitted disease［J］. J Antimicrob Chemother, 1990,25 Suppl A:109⁃114.<br />
［7］	Lassus A. Comparative studies of azithromycin in skin and soft⁃tissue infections and sexually transmitted infections by Neisseria and Chlamydia species［J］. J Antimicrob Chemother, 1990,25 Suppl A:115⁃121.<br />
［8］	Whatley JD, Thin RN, Mumtaz G, et al. Azithromycin vs doxy⁃cycline in the treatment of non⁃gonococcal urethritis［J］. Int J STD AIDS, 1991,2（4）:248⁃251. doi: 10.1177/095646249100200404.<br />
［9］	Martin DH, Mroczkowski TF, Dalu ZA, et al. A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. The Azithromycin for Chlamydial Infections Study Group［J］. N Engl J Med, 1992,327（13）:921⁃925. doi: 10.1056/NEJM199209243271304.<br />
［10］	Nilsen A, Halsos A, Johansen A, et al. A double blind study of single dose azithromycin and doxycycline in the treatment of chlamydial urethritis in males［J］. Genitourin Med, 1992,68（5）:325⁃327.<br />
［11］	Ossewaarde JM, Plantema FH, Rieffe M, et al. Efficacy of single⁃dose azithromycin versus doxycycline in the treatment of cervical infections caused by Chlamydia trachomatis［J］. Eur J Clin Microbiol Infect Dis, 1992,11（8）:693⁃697.<br />
［12］	Hammerschlag MR, Golden NH, Oh MK, et al. Single dose of azithromycin for the treatment of genital chlamydial infections in adolescents［J］. J Pediatr, 1993,122（6）:961⁃965.<br />
［13］	Lister PJ, Balechandran T, Ridgway GL, et al. Comparison of azithromycin and doxycycline in the treatment of non⁃gonococcal urethritis in men［J］. J Antimicrob Chemother, 1993,31 Suppl E:185⁃192.<br />
［14］	Lauharanta J, Saarinen K, Mustonen MT, et al. Single⁃dose oral azithromycin versus seven⁃day doxycycline in the treatment of non⁃gonococcal urethritis in males［J］. J Antimicrob Chemother, 1993,31 Suppl E:177⁃183.<br />
［15］	Steingrímsson O, Olafsson JH, Thórarinsson H, et al. Single dose azithromycin treatment of gonorrhea and infections caused by C. trachomatis and U. urealyticum in men［J］. Sex Transm Dis, 1994,21（1）:43⁃46.<br />
［16］	Horner M, Heller⁃Vitouch C, Ziegler C, et al. Azithromycin in the treatment of chlamydial cervicitis and urethritis［J］. Acta Dermatovenerol A.P.A, 1995,4,95（3）:121⁃125.<br />
［17］	Stamm WE, Hicks CB, Martin DH, et al. Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men. A randomized double⁃blind study［J］. JAMA, 1995, 274（7）: 545⁃549.<br />
［18］	Thorpe EM, Stamm WE, Hook EW, et al. Chlamydial cervicitis and urethritis: single dose treatment compared with doxycycline for seven days in community based practises［J］. Genitourin Med, 1996,72（2）:93⁃97.<br />
［19］	Gruber F, Tomic D, Brajac I. Comparative trial with azithromycin and doxycycline in gonococcal and chlamydial infections in females ［J］. G Ital Dermatol Venereol,1996,131:403⁃406.<br />
［20］	Hillis SD, Coles FB, Litchfield B, et al. Doxycycline and azithromycin for prevention of chlamydial persistence or recurrence one month after treatment in women. A use⁃effectiveness study in public health settings［J］. Sex Transm Dis, 1998,25（1）:5⁃11.<br />
［21］	Tan HH, Chan RK. An open label comparative study of azithromycin and doxycycline in the treatment of non⁃gonococcal urethritis in males and Chlamydia trachomatis cervicitis in female sex workers in an STD clinic in Singapore［J］. Singapore Med J, 1999,40（8）:519⁃523.<br />
［22］	Sendag F, Terek C, Tuncay G, et al. Single dose oral azithromycin versus seven day doxycycline in the treatment of non⁃gonococcal mucopurulent endocervicitis［J］. Aust N Z J Obstet Gynaecol, 2000,40（1）:44⁃47.<br />
［23］	Skerk V, Schönwald S, Strapac Z, et al. Duration of clinical symptoms in female patients with acute urethral syndrome caused by Chlamydia trachomatis treated with azithromycin or doxycycline［J］. J Chemother, 2001,13（2）:176⁃181. doi: 10.1179/joc.2001.13.2.176.<br />
［24］	Rustomjee R, Kharsany AB, Connolly CA, et al. A randomized controlled trial of azithromycin versus doxycycline/ciprofloxacin for the syndromic management of sexually transmitted infections in a resource⁃poor setting［J］. J Antimicrob Chemother, 2002,49（5）:875⁃878.<br />
［25］	Jang D, Sellors J, Howard M, et al. Correlation between culture testing of swabs and ligase chain reaction of first void urine from patients recently treated for Chlamydia trachomatis［J］. Sex Transm Infect, 2003,79（3）:237⁃239.<br />
［26］	Guven MA, Gunyeli I, Dogan M, et al. The demographic and behavioural profile of women with cervicitis infected with Chlamydia trachomatis, Mycoplasma hominis and Ureaplasma urealyticum and the comparison of two medical regimens［J］. Arch Gynecol Obstet, 2005,272（3）:197⁃200. doi: 10.1007/s00404⁃ 005⁃0734⁃2.<br />
［27］	Schwebke JR, Rompalo A, Taylor S, et al. Re⁃evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens⁃⁃a randomized clinical trial［J］. Clin Infect Dis, 2011,52（2）:163⁃170. doi: 10.1093/cid/ciq074.<br />
［28］	Manhart LE, Gillespie CW, Lowens MS, et al. Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial［J］. Clin Infect Dis, 2013,56（7）:934⁃942. doi: 10.1093/cid/cis1022.<br />
［29］	Geisler WM, Uniyal A, Lee JY, et al. Azithromycin versus doxy⁃cycline for urogenital Chlamydia trachomatis infection［J］. N Engl J Med, 2015,373（26）:2512⁃2521. doi: 10.1056/NEJMoa1502599.<br />
［30］	Kong FY, Hocking JS. Treatment challenges for urogenital and anorectal Chlamydia trachomatis［J］. BMC Infect Dis, 2015,15:293. doi: 10.1186/s12879⁃015⁃1030⁃9.<br />
［31］	Parnham MJ, Erakovic HV, Giamarellos⁃Bourboulis EJ, et al. Azithromycin: mechanisms of action and their relevance for clinical applications［J］. Pharmacol Ther, 2014,143（2）:225⁃245. doi: 10.1016/j.pharmthera.2014.03.003.<br />
［32］	Rank RG, Yeruva L. Hidden in plain sight: chlamydial gastrointestinal infection and its relevance to persistence in human genital infection［J］. Infect Immun, 2014,82（4）:1362⁃1371. doi: 10.1128/IAI.01244⁃13.<br />
［33］	Heiligenberg M, Lutter R, Pajkrt D, et al. Effect of HIV and chlamydia infection on rectal inflammation and cytokine concentrations in men who have sex with men［J］. Clin Vaccine Immunol, 2013,20（10）:1517⁃1523. doi: 10.1128/CVI.00763⁃12.<br />
［34］	Zheng S, Matzneller P, Zeitlinger M, et al. Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects［J］. Antimicrob Agents Chemother, 2014,58（11）:6675⁃6684. doi: 10.1128/AAC.02904⁃14.<br />
［35］	Vodstrcil LA, McIver R, Huston WM, et al. The Epidemiology of Chlamydia trachomatis organism load during genital infection: a systematic review［J］. J Infect Dis, 2015,211（10）:1628⁃1645. doi: 10.1093/infdis/jiu670.<br />

[1]	邵丽丽马璟玥练婷婷魏世娟任杰刘全忠. 不同途径接种衣原体后小鼠多脏器衣原体检测分析[J]. 中华皮肤科杂志, 2019, 52(8): 554-560.
[2]	刘兰兰李武孙思张莉张涛吕纯芳陈忠伟罗珍冑陈祥生. 生殖道沙眼衣原体分子流行病学研究进展[J]. 中华皮肤科杂志, 2019, 52(8): 582-585.
[3]	雷文波何蓓聂倩文雅婷赵钰琦李忠玉. 沙眼衣原体pORF5质粒蛋白通过HMGB1抑制细胞凋亡机制初步研究[J]. 中华皮肤科杂志, 2019, 52(8): 548-553.
[4]	梁源刘玲玲王珊赵作涛马琳向欣顾恒陈崑王华易红陈谨萍张金桃姚志荣郭一峰陈戟程颖朱学骏. 0.03%他克莫司软膏长期间歇维持治疗儿童特应性皮炎的多中心随机对照临床研究[J]. 中华皮肤科杂志, 2019, 52(8): 519-524.
[5]	雷杰豪樊奇敏陈荣许爱娥. 白癜风患者窄谱中波紫外线治疗效果与光疗反应的关系及相关因素分析[J]. 中华皮肤科杂志, 2019, 52(4): 259-262.
[6]	翟寒月宋益兴. 585 nm脉冲染料激光治疗儿童传染性软疣的临床观察[J]. 中华皮肤科杂志, 2019, 52(3): 195-197.
[7]	关欣张春雷. 英夫利西单抗长疗程治疗中重度寻常性银屑病的疗效评价[J]. 中华皮肤科杂志, 2019, 52(2): 86-89.
[8]	张静薛峤范文葛魏梅王玲赵军丁浩陶晓瑜. 联用糖皮质激素治疗老年头面部带状疱疹的疗效[J]. 中华皮肤科杂志, 2018, 51(9): 670-672.
[9]	肖媛媛徐子刚徐哲向欣刘盈马琳杨舟. 长春新碱联合糖皮质激素治疗11例婴儿期Kasabach-Merritt综合征[J]. 中华皮肤科杂志, 2018, 51(8): 601-603.
[10]	黄骏许爱娥. 反射式共聚焦显微镜和皮肤镜在评估黑变病综合疗法效果中的应用[J]. 中华皮肤科杂志, 2018, 51(6): 440-442.
[11]	梁韵婷苏向阳卢荣标黄芳朱国兴赖维陆春. 奥马珠单抗治疗慢性自发性荨麻疹疗效与安全性的Meta分析[J]. 中华皮肤科杂志, 2018, 51(6): 472-475.
[12]	陈文韬薛耀华黄进梅杨结仪赵云虎蓝银苑方铭恒郑碧英郑和平. 体外诱导沙眼衣原体持续性感染对宿主细胞凋亡的调控[J]. 中华皮肤科杂志, 2018, 51(5): 347-351.
[13]	黄丹鞠梅常宝珠陈旭张小华朱艳周亚男许南陈崑顾恒. 51例女童尖锐湿疣临床分析[J]. 中华皮肤科杂志, 2018, 51(5): 363-365.
[14]	黄骏胡文婷章玲玲许爱娥. 复方甘草酸苷注射液治疗黄褐斑疗效评估[J]. 中华皮肤科杂志, 2018, 51(4): 299-301.
[15]	王伟霞李敏邓丽娜吴华娟毋婷李云飞李雪莉. 外用重组牛碱性成纤维细胞生长因子治疗激素依赖性皮炎的随机、双盲、安慰剂对照观察[J]. 中华皮肤科杂志, 2018, 51(3): 217-220.